Regorafenib
- Generic Name
- Regorafenib
- Brand Names
- Stivarga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15ClF4N4O3
- CAS Number
- 755037-03-7
- Unique Ingredient Identifier
- 24T2A1DOYB
- Background
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
- Indication
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresecta...
- Associated Conditions
- Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
Regorafenib in Relapsed Glioblastoma
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Istituto Oncologico Veneto IRCCS
- Target Recruit Count
- 119
- Registration Number
- NCT02926222
- Locations
- 🇮🇹
IRCCS "Saverio de Bellis, Castellana Grotte, BA, Italy
🇮🇹Azienda Ospedaliera "G.Rummo", Benevento, BR, Italy
🇮🇹istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori, Cesena, FC, Italy
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-22
- Last Posted Date
- 2023-01-10
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 25
- Registration Number
- NCT02910843
- Locations
- 🇨🇭
St. Claraspital Basel, Basel, Switzerland
🇨🇭Universitätsspital Basel, Basel, Switzerland
🇨🇭Inselspital Bern, Bern, Switzerland
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
- First Posted Date
- 2016-09-05
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT02889328
- Locations
- 🇰🇷
Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of
Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2020-03-10
- Target Recruit Count
- 299
- Registration Number
- NCT02835924
- Locations
- 🇪🇸
Spanish Cooperative Group for the Treatment of Digestive Tumors, Madrid, Spain
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
- First Posted Date
- 2016-06-09
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT02795156
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Florida Cancer Specialists - South, Fort Myers, Florida, United States
🇺🇸Florida Cancer Specialists - East, West Palm Beach, Florida, United States
A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)
- Conditions
- Interventions
- First Posted Date
- 2016-06-02
- Last Posted Date
- 2019-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 363
- Registration Number
- NCT02788279
- Locations
- 🇺🇸
Yale Cancer Center; Medical Oncology, New Haven, Connecticut, United States
🇺🇸Florida Cancer Specialists; SCRI, Fort Myers, Florida, United States
🇺🇸Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy), Jacksonville, Florida, United States
A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
- First Posted Date
- 2016-05-16
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Australasian Gastro-Intestinal Trials Group
- Target Recruit Count
- 250
- Registration Number
- NCT02773524
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸Bon Secours Cancer Institute, Midlothian, Virginia, United States
🇦🇺Canberra Hospital, Canberra, Australian Capital Territory, Australia
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
- First Posted Date
- 2016-04-13
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 21
- Registration Number
- NCT02736305
- Locations
- 🇸🇬
National Cancer Centre Singapore, Singapore, Singapore
Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2019-02-28
- Target Recruit Count
- 55
- Registration Number
- NCT02699073
- Locations
- 🇫🇷
Hôpital Pitié Salpêtrière, Paris, France
🇫🇷Hôpitlal Henri Mondor, Créteil, France
🇫🇷Hôpital Saint Antoine, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.